Jyong Biotech (MENS) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Stablecoin Development (SDEV) has outperformed Jyong Biotech (MENS) over the past year, losing 66.8% versus a loss of 95.9%. Jyong Biotech is the larger company by market cap ($159.7 million vs $103.0 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | SDEV |
|---|---|---|
| Share price | $2.10 | $1.99 |
| Market cap | $159.66M | $102.99M |
| 1-day change | +2.44% | -28.42% |
| YTD return | -46.84% | -92.94% |
| 1-year return | -95.89% | -66.83% |
| 5-year return | — | -99.94% |
| EPS (TTM) | $-0.06 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $99.75 |
| 52-week low | $1.43 | $0.78 |
| Distance from 52-week high | -96.67% | -98.01% |
| Average volume | 45.62K | 11.74M |
| Shares outstanding | 74.23M | 51.75M |
| Employees | 27 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDEV has outperformed MENS by 29.1 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
MENS vs SDEV FAQ
Which is bigger, Jyong Biotech or Stablecoin Development?
Jyong Biotech (MENS) is larger, with a market capitalization of $159.66M compared with $102.99M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, MENS or SDEV?
SDEV returned -66.83% over the past 12 months, compared with -95.89% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.